Regeneron(REGN)
Focus: Regeneron is a large-cap publicly traded biotechnology company with $13.1B in FY2025 revenue, headquartered in Tarrytown, NY, specializing in small molecules and biologics across ophthalmology, oncology, immunology, dermatology, and rare diseases.
Profile data last refreshed 22h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
13,000
Open Jobs
525+28 this month
Hot — 376 jobs added in 30d
Net +28 (376 new, 348 removed). Aggressive expansion phase.
Should You Work at Regeneron?
AI assessmentRegeneron offers financial stability and research depth in a proven franchise, but career longevity depends on successful EYLEA HD transition and Phase 3 pipeline conversion amid high single-product revenue risk.
Why Work Here
- EYLEA HD outsold legacy EYLEA for the first time in Q2 2026, signaling successful product innovation and market transition within the core franchise.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$13.1B
Key Products
$74M Part DStable
Peak
Flagship revenue engine representing 85% of company revenue; dominates wet AMD market but faces biosimilar and competitive pressure.
Help build intelligence for Regeneron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.